J&J's IMAAVY Shows Sustained Disease Control In New GMG Data
(RTTNews) - Tuesday, Johnson & Johnson (JNJ) said new data from the Phase 2/3 long-term extension study showed sustained disease control through two years, along with improvements in daily function and muscle strength and reduced corticosteroid use in anti-AChR-positive adolescen
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.